Government Briefs

Did Someone Say Profit? The debate over potential conflicts of interest in science may be a hot topic among life scientists (The Scientist, Oct. 16, 1989, page 1). But judging from the comments of two Washington policymakers, the debate hasn’t filtered down to all segments of the scientific community. Sen. Pete Domenici (R-N.M.) recently gave a speech marking a new report from the National Academy of Sciences on opportunities in materials science that emphasizes how industry, academia, a

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The debate over potential conflicts of interest in science may be a hot topic among life scientists (The Scientist, Oct. 16, 1989, page 1). But judging from the comments of two Washington policymakers, the debate hasn’t filtered down to all segments of the scientific community. Sen. Pete Domenici (R-N.M.) recently gave a speech marking a new report from the National Academy of Sciences on opportunities in materials science that emphasizes how industry, academia, and government must work together to maintain U.S. leadership in the field. Following the speech, Domenici was asked how the government would make sure that individuals did not profit from work donewith public funding. “I don’t see the problem,” Domenici said. “We’ll never make any progress in our economy unless someone can profit from a discovery. If I had to choose between holding back development, and letting an individual profit from publicly supported research, I’d opt for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies